In-Solution Virus Capture Assay Helps Deconstruct Heterogeneous Antibody Recognition of Human Immunodeficiency Virus Type 1
- 1 April 2010
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (7), 3382-3395
- https://doi.org/10.1128/jvi.02363-09
Abstract
Human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) on whole virions is heterogeneous, so molecular analysis of Env with monoclonal antibodies (MAbs) is challenging. Virus capture assays (VCAs) involving immobilized MAbs are typically used, but these assays suffer from immobilization artifacts and do not provide binding constants. Furthermore, we show here that certain HIV-1 neutralizing MAbs, including 2G12, 4E10, 2F5, Z13e1, and D5, will capture virion particles completely devoid of Env. We modified the VCA such that MAbs and virions are incubated in solution, and unbound MAbs are removed prior to the capture step. This modification nearly eliminated evidence of Env-independent binding by MAbs to virions and allowed determination of apparent affinity constants in solution. Three important qualitative observations were further revealed. First, neutralizing MAbs 2F5, 4E10, and Z13e1 against the membrane-proximal external region (MPER) of HIV-1 gp41 were found to capture virions efficiently only if a significant amount of uncleaved gp160 or synthetic MPER peptide was present. Second, we show how non-native forms of Env vary by Env genotype and that Env from HIV-1 JR-FL is more homogeneously trimeric than that from HIV-1 JR-CSF . Third, we determined that Env containing all or parts of gp41, including uncleaved gp160, binds spontaneously to free virions. This exogenous Env is an indiscriminate molecular “bridge” between Env-specific Ab and virions and can affect VCA analyses, particularly using pseudotyped virions. Heterogeneity in Env from endogenous and exogenous sources might also subvert humoral immunity to HIV-1, so in-solution VCAs may help to dissect this heterogeneity for vaccine design purposes.This publication has 93 references indexed in Scilit:
- An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virionsProceedings of the National Academy of Sciences of the United States of America, 2008
- Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralizationVirology, 2008
- Molecular architecture of native HIV-1 gp120 trimersNature, 2008
- Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimeticsVirology, 2008
- A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesProceedings of the National Academy of Sciences of the United States of America, 2008
- N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virusVirology, 2008
- Peptide Mimic of the HIV Envelope gp120–gp41 InterfaceJournal of Molecular Biology, 2008
- Photoinduced Reactivity of the HIV-1 Envelope Glycoprotein with a Membrane-Embedded Probe Reveals Insertion of Portions of the HIV-1 Gp41 Cytoplasmic Tail into the Viral MembraneBiochemistry, 2008
- Some antiphospholipid antibodies recognize conformational epitopes shared by β2‐glycoprotein I and the homologous catalytic domains of several serine proteasesArthritis & Rheumatism, 2007
- Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibodyNature Structural & Molecular Biology, 2006